Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: A long-term follow-up

British Journal of Haematology

Volumn 130, Issue 5, 2005, Pages 747-751

  Kahl, Christoph ^b   Leisenring, Wendy ^b   Joachim Deeg, H ^b   Chauncey, Thomas R ^b   Flowers, Mary E D ^b   Martin, Paul J ^b   Sanders, Jean E ^b   Storb, Rainer ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Aplastic anaemia; Cyclophosphamide antithymocyte globulin conditioning; Human leucocyte antigen matched marrow grafts

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE; THYMOCYTE ANTIBODY; ANTINEOPLASTIC AGENT; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; APLASTIC ANEMIA; ARTICLE; CARCINOGENESIS; CARCINOMA; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ADOLESCENT; ALLOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CHILD; KARNOFSKY PERFORMANCE STATUS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PRESCHOOL CHILD; SURVIVAL RATE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; ANTILYMPHOCYTE SERUM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KARNOFSKY PERFORMANCE STATUS; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 27244460780     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05667.x     Document Type: Article

References (12)

1. Bhatia S. Bhatia R. ( 2004) Secondary malignancies after hematopoietic cell transplantation. In: Thomas' Hematopoietic Cell Transplantation ( ed. by K.G. Blume S.J. Forman F.R. Appelbaum p. 962 977. Blackwell Publishing Ltd., Malden, MA
2. Gluckman E. ( 2002) Association of CD34 cell dose with hematopoietic recovery, infections, and other outcomes after HLA-identical sibling bone marrow transplantation. Blood, 99, 2726 2733.
3. Curtis R.E. Metayer C. Rizzo J.D. Socié G. Sobocinski K.A. Flowers M.E.D. Travis W.D. Travis L.B. Horowitz M.M. Deeg H.J. ( 2005) Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood, 105, 3802 3811.
4. Pepe M.S. Longton G. Thornquist M. ( 1991) A qualifier Q for the survival function to describe the prevalence of a transient condition. Statistics in Medicine, 10, 413 421.
5. Sanders J.E. Hawley J. Levy W. Gooley T. Buckner C.D. Deeg H.J. Doney K. Storb R. Sullivan K. Witherspoon R. Appelbaum F.R. ( 1996) Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood, 87, 3045 3052.
6. Schmitz N. ( 2004) Peripheral blood hematopoietic cells for allogeneic transplantation. In: Thomas' Hematopoietic Cell Transplantation ( ed. by K.G. Blume S.J. Forman F.R. Appelbaum p. 588 598. Blackwell Publishing Ltd., Malden, MA
7. for the European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party ( 1993) Malignant tumors occurring after treatment of aplastic anemia. New England Journal of Medicine, 329, 1152 1157.
8. Storb R. Prentice R.L. Thomas E.D. ( 1977) Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. New England Journal of Medicine, 296, 61 66.
9. Storb R. Prentice R.L. Buckner C.D. Clift R.A. Appelbaum F. Deeg J. Doney K. Hansen J.A. Mason M. Sanders J.E. Singer J. Sullivan K.M. Witherspoon R.P. Thomas E.D. ( 1983a) Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. New England Journal of Medicine, 308, 302 307.
10. Storb R. Prentice R.L. Sullivan K.M. Shulman H.M. Deeg H.J. Doney K.C. Buckner C.D. Clift R.A. Witherspoon R.P. Appelbaum F.R. Sanders J.E. Stewart P.S. Thomas E.D. ( 1983b) Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Annals of Internal Medicine, 98, 461 466.
11. Storb R. Etzioni R. Anasetti C. Appelbaum F.R. Buckner C.D. Bensinger W. Bryant E. Clift R. Deeg H.J. Doney K. Flowers M. Hansen J. Martin P. Pepe M. Sale G. Sanders J. Singer J. Sullivan K.M. Thomas E.D. Witherspoon R.P. ( 1994) Cyclophosphamide combined with antithymocyte globulin in preparation for allogeneic marrow transplants in patients with aplastic anemia. Blood, 84, 941 949.
12. Storb R. Blume K.G. O'Donnell M.R. Chauncey T. Forman S.J. Deeg H.J. Hu W.W. Appelbaum F.R. Doney K. Flowers M.E.D. Sanders J. Leisenring W. ( 2001) Cyclophosphamide and antithymocyte globulin to condition patients with aplastic anemia for allogeneic marrow transplantations: the experience in four centers. Biology of Blood and Marrow Transplantation, 7, 39 44.